Skip to main content
. 2020 Feb 6;46(5):943–953. doi: 10.1007/s00134-019-05919-0

Fig. 3.

Fig. 3

Biomarker concentrations for different non-AKI acute and chronic conditions and by severity of persistent AKI for a urine CCL14, b urine CHI3L1, c plasma cystatin C, d plasma proenkephalin, e urine NGAL, and f urine L-FABP. Open boxes are for different acute and chronic conditions among patients who did not persist at any stage of AKI. Shaded boxes are for patients by persistent AKI stage. Box and whiskers show interquartile ranges and total observed ranges (censored by 1.5 times the box range), respectively